St. Jude’s Durata Linked to Case of Externalized Wire

St. Jude Medical Inc. (STJ)’s Durata, a wire used to connect life-saving defibrillators to the heart, was linked to a rare and dangerous defect in one patient in a report to U.S. regulators.

A doctor voluntarily reported the case of a so-called externalized wire from April 17 to the Food and Drug Administration, according to a posting on the agency’s Maude safety database. The unidentified doctor didn’t tell St. Paul, Minnesota-based St. Jude, according to the FDA’s posting. The company couldn’t immediately confirm the report.

St. Jude stopped selling its Riata wires, known as leads, in December 2010 and recalled them a year later amid reports they could break through the insulation coating and fail to work properly. Durata replaced Riata, and the new product’s insulation coating, called Optim, was designed to prevent the rare defect. No cases of externalized Durata wires have been reported before now.

“All leads are prone to some level of failure and one lead failure does not implicate the entire family of Durata leads,” wrote Raj Denhoy, a Jefferies & Co. analyst in New York, in a note today to investors. “This new report raises questions on whether Durata is truly immune to the same failures that plague Riata and at the very least, will keep up the discussion on whether St. Jude’s smaller diameter leads should be used when other more reliable leads are available.”

Share Decline

St. Jude fell 6 percent to $36.24 at 4:05 p.m. in New York, the biggest drop since December. The shares have dropped 26 percent in the past 12 months.

“The report indicates that it was filed by a physician, but does not provide the device serial number, the name of the physician or the institution, which would enable us to learn more about the circumstances,” Amy Jo Meyer, a spokeswoman for St. Jude, said in an e-mail. “We will make every effort to learn more about this report as quickly as possible.”

There haven’t been any cases of externalized wires on a Durata lead reported to the company, Meyer said.

St. Jude’s declining stock price is an overreaction, David Roman, an analyst at Goldman Sachs in New York, wrote today in a note to investors. Durata’s performance seems to be similar to competitors and its future performance may show a reduction in lead failures, he said.

“The sharp negative reaction in the stock reflects the fear factor of a product recall that we ultimately do not think will materialize,” Roman said. “We see this as an especially compelling opportunity” to buy, he said.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.